| Region: | |
| Category: |
(139 reports matching your criteria)
|
China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medi
5/20/2013 | published by: Access China Management Consulting Ltd.
... a precise chemical structural formula, but also the indications of the majority of traditional Chinese medicines still can not been clearly described by the modern medical terminologies. How the Chinese drug authorities to administer the ...
|
read more...
|
$750.00
|
|
China Pharmaceutical Guidebook Series (3) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products
5/10/2013 | published by: Access China Management Consulting Ltd.
... behind the developed countries. The requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and harmonized. In China, the pharmaceutical regulatory authority ----- ...
|
read more...
|
$750.00
|
|
Hypertension Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ...
|
read more...
|
$2,000.00
|
|
Anti-Obesity Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ...
|
read more...
|
$2,000.00
|
|
Osteoporosis Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ...
|
read more...
|
$2,000.00
|
|
Anti-Tumor Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ...
|
read more...
|
$2,000.00
|
|
Blood Disease Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ...
|
read more...
|
$2,000.00
|
|
Mental Illness Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ...
|
read more...
|
$2,000.00
|
|
Lymphoma Treatment Drugs Markets in China
5/1/2013 | published by: Asia Market Information & Development Company
... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ...
|
read more...
|
$2,000.00
|
|
Biologic Drug R&D in China - Current State and Future Development
5/1/2013 | published by: JZMed, Inc.
... biological medicines. In the recent several years growing numbers of Chinese pharma and biopharma companies have been steadily increasing their investment in innovative drug R&D, including the discovery and development of novel biologics. The current ...
|
read more...
|
$3,685.00
|
|
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
4/30/2013 | published by: GlobalData
... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ...
|
read more...
|
$4,995.00
|
|
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players
4/29/2013 | published by: GBI Research
... latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, ...
|
read more...
|
$3,500.00
|
|
China Pharmaceutical Guidebook Series (2) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Chemical Drugs
4/20/2013 | published by: Access China Management Consulting Ltd.
... to the imported drugs from overseas pharmaceutical manufacturers and producers. By 2012, sales of imported drugs have shared one fourth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates ...
|
read more...
|
$750.00
|
|
Alzheimer Disease Treatment Drugs Markets in China
4/15/2013 | published by: Asia Market Information & Development Company
... continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term ...
|
read more...
|
$2,000.00
|
|
PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
3/31/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
3/1/2013 | published by: GlobalData
... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ...
|
read more...
|
$4,995.00
|
|
Research Report on China’s Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
2/22/2013 | published by: China Research and Intelligence Co., Ltd.
... morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the ...
|
read more...
|
$1,800.00
|
|
PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022
2/15/2013 | published by: GlobalData
... characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. ...
|
read more...
|
$4,995.00
|
|
Research Report on China’s Anti-Alzheimer’s Disease (AD) Drug Market, 2013-2017
1/28/2013 | published by: China Research and Intelligence Co., Ltd.
... 2010. The elderly population in China will exceed 200 million by the end of 2013 and reach 221 million in 2015, accounting for 16% of the population, with a severe population aging trend. Globally, the ...
|
read more...
|
$2,800.00
|